YU2101A - Antiparazitski derivati artemisinina (endoperoksidi) - Google Patents
Antiparazitski derivati artemisinina (endoperoksidi)Info
- Publication number
- YU2101A YU2101A YU2101A YU2101A YU2101A YU 2101 A YU2101 A YU 2101A YU 2101 A YU2101 A YU 2101A YU 2101 A YU2101 A YU 2101A YU 2101 A YU2101 A YU 2101A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- endoperoxides
- artemisinin derivatives
- derivatives
- artemisinin
- treatment
- Prior art date
Links
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical class C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 title abstract 3
- 230000002141 anti-parasite Effects 0.000 title 1
- 239000003096 antiparasitic agent Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 2
- 208000003495 Coccidiosis Diseases 0.000 abstract 1
- 206010023076 Isosporiasis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Pronalazak se odnosi na upotrebu odredjenih C-10 supstituisanih derivata artemizinina, opšte formule (I), za lečenje i/ili profilaksu jedinjenja izazvanih infekcijom sa parazitom, na odredjene nove C-10 supstituisane derivate artemizinina, na postupke za njihovo pripremanje i na farmaceutske kompozicije koje sadrže C-10 supstituisane derivate. Jedinjenja su naročito efikasna u lečenju malarije, neosporoze i kokcidioze.[This invention relates to the use of certain C-10 substituted derivatives of artemisinin of general formula (I) in the treatment and/or prophylaxis of diseases caused by infection with a parasite, certain novel C-10 substitued derivatives of artemisinin, processes for their preparation and pharmaceutical compositions containing such C-10 substituted derivatives. The compounds are particularly effective in the treatment of malaria, neosporosis and coccidiosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98305596 | 1998-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU2101A true YU2101A (sh) | 2005-06-10 |
Family
ID=8234942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU2101A YU2101A (sh) | 1998-07-14 | 1999-07-14 | Antiparazitski derivati artemisinina (endoperoksidi) |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US6984640B1 (sh) |
| EP (2) | EP1095042B9 (sh) |
| JP (1) | JP2002520416A (sh) |
| KR (1) | KR100640113B1 (sh) |
| CN (1) | CN1122035C (sh) |
| AT (1) | ATE314373T1 (sh) |
| AU (1) | AU765860B2 (sh) |
| BG (1) | BG105137A (sh) |
| BR (1) | BR9912810A (sh) |
| CA (1) | CA2337119A1 (sh) |
| DE (1) | DE69929203T2 (sh) |
| DK (1) | DK1095042T5 (sh) |
| ES (1) | ES2257062T4 (sh) |
| HK (1) | HK1040709B (sh) |
| HU (1) | HUP0102851A3 (sh) |
| IL (1) | IL140402A0 (sh) |
| NO (1) | NO20010223L (sh) |
| NZ (1) | NZ509324A (sh) |
| PL (1) | PL345503A1 (sh) |
| PT (1) | PT1095042E (sh) |
| RU (1) | RU2236413C2 (sh) |
| SI (1) | SI1095042T1 (sh) |
| SK (1) | SK542001A3 (sh) |
| TR (1) | TR200100073T2 (sh) |
| UA (1) | UA75325C2 (sh) |
| WO (1) | WO2000004024A1 (sh) |
| YU (1) | YU2101A (sh) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000004024A1 (en) * | 1998-07-14 | 2000-01-27 | Bayer Aktiengesellschaft | Antiparasitic artemisinin derivatives (endoperoxides) |
| ATE334987T1 (de) * | 2002-03-08 | 2006-08-15 | Bayer Healthcare Ag | Artemisininderivate (endoperoxide) mit wirkung gegen parasiten |
| DE102004027871B3 (de) * | 2004-06-08 | 2006-03-16 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von 10α-[4'-(S,S-Dioxothiomorpholin-1'-yl)]-10-desoxo-10-dihydroartemisinin |
| EP1714967A1 (en) * | 2005-04-22 | 2006-10-25 | Bayer HealthCare AG | Antiparasitic artemisinin derivatives |
| WO2008127381A2 (en) * | 2006-10-20 | 2008-10-23 | Johns Hopkins University | Artemisinin derivatives |
| US8193376B2 (en) | 2007-01-01 | 2012-06-05 | Bioderm Research | Artemisinin derivatives with natural amino acids, peptides, and amino sugars for the treatment of infection and topical condition in mammals |
| GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
| EP2285808B1 (en) * | 2008-04-29 | 2013-11-20 | Novartis AG | Spiro-indole derivatives for the treatment of parasitic diseases |
| SI2424523T1 (sl) * | 2009-04-23 | 2012-11-30 | Londonpharma Ltd | Podjezična aerosolna formulacija ki vsebuje dihidroartemezinin |
| US8815942B2 (en) | 2010-10-20 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease |
| RU2466133C1 (ru) * | 2011-06-24 | 2012-11-10 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) | Трициклические органические монопероксиды и способ их получения |
| US9675582B2 (en) | 2011-10-25 | 2017-06-13 | U.S. Phytotherapy, Inc. | Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus |
| US9358261B2 (en) | 2011-10-25 | 2016-06-07 | U.S. Phytotherapy, Inc. | Additional artemisinin and berberine compositions and methods of making |
| US9011892B2 (en) | 2011-10-25 | 2015-04-21 | U.S. Phytotherapy, Inc. | Artemisinin with berberine compositions and methods of making |
| EP2838903B1 (en) * | 2012-04-18 | 2017-09-06 | The Hong Kong University of Science and Technology | Methods and compositions for treating viral infections |
| JP5994059B2 (ja) * | 2012-09-05 | 2016-09-21 | 国立大学法人東京農工大学 | 抗マラリア活性を有するアザアルテミシニン誘導体及びその製造方法 |
| EP3450549B1 (en) * | 2012-10-29 | 2020-09-30 | University Of Rochester | Artemisinin derivatives, methods for their preparation and their use as antimalarial agents |
| WO2015041722A1 (en) | 2013-09-17 | 2015-03-26 | Kryptonite Group, Ltd | Enhanced artemisinin-based combination therapy for treating parasitic mediated disease |
| USD729631S1 (en) | 2013-10-03 | 2015-05-19 | Gk Packaging, Inc. | Bottle |
| USD729632S1 (en) | 2013-10-03 | 2015-05-19 | Gk Packaging, Inc. | Bottle |
| USD730736S1 (en) | 2013-10-03 | 2015-06-02 | Gk Packaging, Inc. | Bottle |
| USD726543S1 (en) | 2013-11-04 | 2015-04-14 | Gk Packaging, Inc. | Bottle |
| USD727160S1 (en) | 2013-11-04 | 2015-04-21 | Gk Packaging, Inc. | Bottle |
| USD726545S1 (en) | 2013-11-04 | 2015-04-14 | Gk Packaging, Inc. | Bottle |
| USD726544S1 (en) | 2013-11-04 | 2015-04-14 | Gk Packaging, Inc. | Bottle |
| CN103664982A (zh) * | 2013-12-06 | 2014-03-26 | 湖南科源生物制品有限公司 | 青蒿素类似物及其制备方法 |
| CN103896960A (zh) * | 2014-01-14 | 2014-07-02 | 李学强 | 一种高效、绿色的青蒿砜制备方法 |
| USD740125S1 (en) | 2014-03-26 | 2015-10-06 | Gk Packaging, Inc. | Bottle |
| USD740677S1 (en) | 2014-03-26 | 2015-10-13 | Gk Packaging, Inc. | Bottle |
| USD742748S1 (en) | 2014-06-13 | 2015-11-10 | Gk Packaging, Inc. | Bottle |
| USD753503S1 (en) | 2014-09-25 | 2016-04-12 | Gk Packaging, Inc. | Bottle |
| USD753502S1 (en) | 2014-09-25 | 2016-04-12 | Gk Packaging, Inc. | Bottle |
| USD746145S1 (en) | 2014-12-04 | 2015-12-29 | GK Packaging, Inc | Bottle |
| USD784820S1 (en) | 2015-02-05 | 2017-04-25 | Gk Packaging, Inc. | Bottle |
| CN105198898A (zh) * | 2015-09-23 | 2015-12-30 | 山东大学（威海） | 一种用于预防和/或治疗癌症的化合物 |
| USD807190S1 (en) | 2015-10-13 | 2018-01-09 | Gk Packaging, Inc. | Bottle |
| USD784821S1 (en) | 2015-10-13 | 2017-04-25 | Gk Packaging, Inc. | Bottle |
| USD774914S1 (en) | 2015-10-13 | 2016-12-27 | Gk Packaging, Inc. | Bottle |
| USD806555S1 (en) | 2017-03-15 | 2018-01-02 | Gk Packaging, Inc. | Bottle |
| JP7306997B2 (ja) | 2017-03-20 | 2023-07-11 | ザ・ブロード・インスティテュート・インコーポレイテッド | 寄生虫性疾患の処置のための化合物および方法 |
| USD825342S1 (en) | 2017-06-02 | 2018-08-14 | Gk Packaging, Inc. | Bottle |
| WO2019180708A1 (en) * | 2018-03-22 | 2019-09-26 | Hadasit Medical Research Services And Development Ltd. | Methods and synergic compositions for treating viral infections |
| USD908011S1 (en) | 2019-04-30 | 2021-01-19 | Gk Packaging, Inc. | Bottle |
| CN110448552B (zh) * | 2019-08-23 | 2023-05-12 | 西南大学 | 二氢青蒿素衍生物在制备抗疟药物中的应用 |
| CN110483547B (zh) * | 2019-08-28 | 2022-08-16 | 西南大学 | 二氢青蒿素的简单酚类偶联物、合成方法及应用 |
| CN110642869B (zh) * | 2019-09-26 | 2022-03-15 | 西南大学 | 二氢青蒿素的硫醚、亚砜与砜衍生物及其应用 |
| USD883798S1 (en) | 2019-09-30 | 2020-05-12 | Gk Packaging, Inc. | Bottle |
| CN114276365B (zh) * | 2021-12-30 | 2023-06-13 | 威胜生物医药(苏州)股份有限公司 | 一种蒿甲醚杂质脱水双氢青蒿素的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225427A (en) | 1988-10-04 | 1993-07-06 | Hoechst Aktiengesellschaft | 10-substituted ether derivatives of dihydroartemisinin, process for their preparation and their use as antiprotozoal agents |
| CN1041595A (zh) | 1988-10-04 | 1990-04-25 | 赫彻斯特股份公司 | 新蒿属素衍生物，其制法及其作为抗原虫剂的应用， |
| CN1028294C (zh) | 1989-12-21 | 1995-04-26 | 中国科学院上海药物研究所 | 一类含氮青蒿素衍生物的合成 |
| TW198722B (sh) | 1990-05-07 | 1993-01-21 | Hoechst Ag | |
| US5225562A (en) * | 1990-08-10 | 1993-07-06 | Mcchesney James D | Method of preparing (+)-deoxoartemisinin and selected analogues of (+)-deoxoartemisinin |
| AU659505B2 (en) * | 1991-10-14 | 1995-05-18 | University Of Sydney, The | Cyclic peroxyacetal compounds |
| JPH05203550A (ja) * | 1992-01-24 | 1993-08-10 | Shimadzu Corp | 界面強度測定方法及びその測定装置 |
| CN1049435C (zh) * | 1994-11-09 | 2000-02-16 | 中国科学院上海药物研究所 | 含苯基和杂环基的青蒿素衍生物及其制备方法 |
| WO1997008182A1 (en) * | 1995-08-24 | 1997-03-06 | Merck & Co., Inc. | Process for the preparation of imidazolyl macrolide immunosuppressants |
| US6160004A (en) * | 1997-12-30 | 2000-12-12 | Hauser, Inc. | C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities |
| WO2000004024A1 (en) * | 1998-07-14 | 2000-01-27 | Bayer Aktiengesellschaft | Antiparasitic artemisinin derivatives (endoperoxides) |
| US6649647B1 (en) | 1998-07-14 | 2003-11-18 | Richard Haynes | Trioxane derivatives |
-
1999
- 1999-07-14 WO PCT/GB1999/002267 patent/WO2000004024A1/en active IP Right Grant
- 1999-07-14 PL PL99345503A patent/PL345503A1/xx not_active Application Discontinuation
- 1999-07-14 DK DK99933043T patent/DK1095042T5/da active
- 1999-07-14 EP EP99933043A patent/EP1095042B9/en not_active Expired - Lifetime
- 1999-07-14 HU HU0102851A patent/HUP0102851A3/hu unknown
- 1999-07-14 UA UA2001021049A patent/UA75325C2/uk unknown
- 1999-07-14 ES ES99933043T patent/ES2257062T4/es not_active Expired - Lifetime
- 1999-07-14 DE DE69929203T patent/DE69929203T2/de not_active Expired - Fee Related
- 1999-07-14 TR TR2001/00073T patent/TR200100073T2/xx unknown
- 1999-07-14 JP JP2000560130A patent/JP2002520416A/ja active Pending
- 1999-07-14 IL IL14040299A patent/IL140402A0/xx unknown
- 1999-07-14 SI SI9930873T patent/SI1095042T1/sl unknown
- 1999-07-14 RU RU2001104417/04A patent/RU2236413C2/ru not_active IP Right Cessation
- 1999-07-14 NZ NZ509324A patent/NZ509324A/en unknown
- 1999-07-14 PT PT99933043T patent/PT1095042E/pt unknown
- 1999-07-14 EP EP05017342A patent/EP1655302A3/en not_active Withdrawn
- 1999-07-14 CN CN99810650A patent/CN1122035C/zh not_active Expired - Lifetime
- 1999-07-14 CA CA002337119A patent/CA2337119A1/en not_active Abandoned
- 1999-07-14 AU AU49218/99A patent/AU765860B2/en not_active Ceased
- 1999-07-14 US US09/743,827 patent/US6984640B1/en not_active Expired - Lifetime
- 1999-07-14 KR KR1020017000572A patent/KR100640113B1/ko not_active IP Right Cessation
- 1999-07-14 AT AT99933043T patent/ATE314373T1/de not_active IP Right Cessation
- 1999-07-14 SK SK54-2001A patent/SK542001A3/sk unknown
- 1999-07-14 YU YU2101A patent/YU2101A/sh unknown
- 1999-07-14 BR BR9912810-1A patent/BR9912810A/pt not_active IP Right Cessation
-
2001
- 2001-01-10 BG BG105137A patent/BG105137A/xx unknown
- 2001-01-12 NO NO20010223A patent/NO20010223L/no unknown
-
2002
- 2002-03-27 HK HK02102362.4A patent/HK1040709B/zh not_active IP Right Cessation
-
2006
- 2006-01-09 US US11/329,297 patent/US7452915B2/en not_active Expired - Fee Related
- 2006-01-09 US US11/329,274 patent/US7439238B2/en not_active Expired - Fee Related
- 2006-01-09 US US11/329,275 patent/US20060287305A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU2101A (sh) | Antiparazitski derivati artemisinina (endoperoksidi) | |
| WO2004007457A3 (en) | Substituted benzylamine derivatives and methods of use | |
| IL176298A (en) | Imidazo [5,4 – c] pyridine compounds, preparations containing them and these compounds for use in the treatment and prevention of viral infection | |
| AUPR213700A0 (en) | Antiviral agents | |
| RS60503A (en) | Substituted alkylamine derivatives and methods of use | |
| HK1069169A1 (en) | Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| YU79304A (sh) | Antiparazitski derivati artemizinina (endoperoksidi) | |
| WO2002026726A3 (en) | Antiviral compositions and methods of use | |
| WO2002072581A3 (en) | Pyrazolopyriadine derivatives | |
| WO2002018353A3 (en) | Oxazolidinone chemotherapeutic agents | |
| GB0025688D0 (en) | Macrolides | |
| IL159521A0 (en) | Tricyclic pyridines for use in treatment of conditions mediated by crf | |
| WO2002083641A3 (en) | Amino-aza-cyclohexanes for the treatment of malaria | |
| AU2003227008A1 (en) | 2-methylthiazolidine-2,4-dicarboxylic acid and the salts thereof used for the treatment of neurodegenerative diseases | |
| MY122986A (en) | Pyrrolotriazolopyrimidinone derivatives |